ClinicalTrials.gov
ClinicalTrials.gov Menu

High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00080977
Recruitment Status : Unknown
Verified June 2005 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
First Posted : April 8, 2004
Last Update Posted : December 19, 2013
Sponsor:
Information provided by:
National Cancer Institute (NCI)

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Unknown
  Primary Completion Date : No date given
  Study Completion Date : No date given